Aim: To estimate the number of people with open angle (OAG) and angle closure glaucoma (ACG) in 2010 and 2020. Methods: A review of published data with use of prevalence models. Data from population based studies of age specific prevalence of OAG and ACG that satisfied standard definitions were used to construct prevalence models for OAG and ACG by age, sex, and ethnicity, weighting data proportional to sample size of each study. Models were combined with UN world population projections for 2010 and 2020 to derive the estimated number with glaucoma. Results: There will be 60.5 million people with OAG and ACG in 2010, increasing to 79.6 million by 2020, and of these, 74% will have OAG. Women will comprise 55% of OAG, 70% of ACG, and 59% of all glaucoma in 2010. Asians will represent 47% of those with glaucoma and 87% of those with ACG. Bilateral blindness will be present in 4.5 million people with OAG and 3.9 million people with ACG in 2010, rising to 5.9 and 5.3 million people in 2020, respectively. Conclusions: Glaucoma is the second leading cause of blindness worldwide, disproportionately affecting women and Asians.

GLAUCOMA is the second leading cause of world blindness,¹ equalling the visual disability caused by trachoma and exceeded only by cataract. A group of recent population-based studies^2-13 has detailed its impact on European- and African-derived persons in the United States, Europe, Australia, the Caribbean, Tanzania, and Mongolia. There are substantial differences in the prevalence and incidence of glaucoma between European- and African-derived persons¹² that appear to be genetically based. Present data on glaucoma do not include large well-designed studies of the many important ethnic groups in the world. In particular, to our knowledge, there are no population-based studies of glaucoma in Hispanic persons.

Purpose To estimate the change in iris cross-sectional (CS) area with pupil dilation using anterior segment optical coherence tomography comparing eyes with angle closure (AC) to open angle glaucoma (OAG). Methods Sixty-five patients from the Wilmer Glaucoma service, 36 with definite or suspected OAG and 29 with definite or suspected AC, underwent anterior segment optical coherence tomography imaging under 3 conditions (pupil constriction to light, physiologic dilation in the dark, and after pharmacologic dilation). The nasal and temporal iris CS areas were measured with custom software, 3 times in each of 4 meridians. The principal outcome variables were iris CS area and change in iris CS area/mm pupil diameter change. The relation of these parameters to potential variables that would influence iris area was estimated by multivariate regression. Results CS area was smaller in eyes with larger pupil diameter, those that had undergone trabeculectomy, and those of European-derived persons (P<0.05 for all in a univariate analysis). In a multivariate model with CS area as the dependent variable, larger pupil diameter (with a 0.19 mm² decrease in CS area for each 1 mm of pupil enlargement, P=0.0002), and trabeculectomy remained significant factors. In a second multivariate model, AC irides had less change in CS area/mm pupil enlargement than OAG or OAG suspects (P=0.01). Change in iris CS area was essentially complete in 5 seconds (n=10 eyes). Conclusions The iris loses nearly half its volume from a pupil diameter of 3 to 7 mm, probably by eliminating extracellular fluid. Smaller iris CS area change with physiologic pupil dilation is a potential risk factor for AC. Dynamic iris CS area change deserves testing as a prospective indicator of AC.